A Subway employee shared on Instagram a photo of a penis at rest on foot-long sandwich bread.
A sandwich maker at a Subway franchise has been fired for putting his own meat on the bun, the company has confirmed.
See: euphemism.
"This isolated incident is not representative of SUBWAY Sandwich Artists?. These actions are not tolerated and the franchisee took immediate action to terminate the two employees involved," a Subway spokesman said in a statement emailed Tuesday to CNBC.
The questionable deeds came to public attention Monday after the Huffington Post republished images from Instagram of self-identified Subway employees misbehaving. One showed a penis at rest on foot-long sandwich bread in what appears to be the restaurant's preparation area. However, the employee told the Huffington Post the image was actually taken at his home.
Another employee picture shows a bottle filled with a frozen substance. "Today at work I froze my pee," the caption states.
Subway declined to confirm the employees names or location of the restaurant.
Plenty of other restaurant employees have been fired for public pictures of inappropriate work behavior.
The obvious question -- What were they thinking ? actually has an answer, according to the experts.
"Though people have been warned many times about what you're not supposed to do, etiquette on the Internet, a lot of people think it doesn't really matter. It doesn't really count. They often think they are invincible," said psychologist Susan Lipkins. "It's like driving fast or doing drugs. There's a huge amount of denial. They think they are invincible, it's a Superman complex. They think its' not going to happen to them."
"Kids get away with so much on the Internet, when they finally get caught it's a surprise. It's sort of like a thief, they start small," she said.
The situation isn't that much unlike powerful politicians who have been busted for sexting or frequenting prostitutes, Lipkins said. "What I think happen to people like him (former U.S. Congressman Anthony Weiner) and people who are in power, they no longer see the line, their power has allowed them to do it. They are either unquestioned or able to step over the line," she said.
But as for the fast-food workers?
"I don't think the kids feel powerful in the same way. I think they feel anonymous. I think they don't think they will get caught," she said.
Other factors come into play.
"Teenagers are much more prone to stupid behavior, not thinking before they act," said psychologist Neil Bernstein. "They don't ask: 'What's going to happen if I do this?'"
"I think this is a culture of sensational outrageousness. And online is the perfect venue for expressing that," said Bernstein, who is also the author of "How to keep your teenager out of trouble and what to do if you can't,"
"Just how far are we gonna go? It's extreme," he said.
?By CNBC's Amy Langfield. Follow her on Twitter @AmyLangfield
23 July 2013, Lagos ? As part of measures put in place to boost electricity supply in the country, Nigeria and India have concluded plans to set up an off-grid solar powered system across selected locations in Nigeria.
Already, an agreement to actualise the objectives of the project has been signed by the two parties involved.
A statement from the ministry of power in Abuja disclosed that the ministry and Indian-based power firm, Bharat Heavy Electricals had put pen to paper to commence with the project.
According to the statement, from the plan, which was unveiled, Bharat Heavy Electricals has been given the nod to commence studies on the project with a view to climaxing it with the setting-up of solar based independent projects in selected locations starting with Bida in Niger State.
Although, details of the expected capacity and funding mechanism for the project were not disclosed, the Permanent Secretary in the ministry, Godknows Igali, had expressed delight at the prospect of the proposed project.
Igali stated that the project would unbundle the enormous potentials in Nigeria?s power sector, assuring that Nigeria?s open door policy for genuine investors in the power sector and fruitful collaboration with the Indian company would be leveraged to make a success of the project.
The Secretary of Government of India, Department of Heavy Industries, Dr. Sutanu Behuria, who led the team at the signing ceremony expressed India?s interest in the provision of funds in various forms for the development of Nigeria?s power sector.
Behuria stated that Bharat had got the necessary capacity to deliver on the project considering its experience from operations in 12 African countries, which he described as robust and will come in handy in assisting Nigeria realise its vision for uninterrupted power supply.
Meanwhile, the Nigerian Electricity Regulatory Commission, NERC, has said that disclosure of vital information as demanded by the Freedom of Information, FOI, Act 2010 was necessary to douse unnecessary tensions in such complex sector like Nigeria?s Electricity Supply Industry, NESI.
Chairman of NERC, Dr. Sam Amadi, stated at an interactive session with chief executives of ministries, departments and agencies, MDAs, of the federal government alongside the House of Representatives Committee on reform of government in Abuja that contrary to insinuations, an open government enjoys more stability and efficiency.
Amadi explained that embracing the FOI law would not provide an organisation the freedom to act in justifiable manners, adding that NERC as a regulator would remain open to required disclosures as mandated by the law.
?The most difficult challenge to the FOI law is conceptual hurdle because of the erroneous belief of what disclosure would do to an organisation, contrary to that, an open government is more stable and efficient as feedbacks from citizens and customers improve organisational processes and outcomes,? Amadi stated.
He also advised managers of government agencies to understand that without transforming the corporate culture of their agencies, making the paradigm shift required to fully embrace the FOI law would be challenging.
Abilene Christian Schools is
pleased to announce it has named Kirk Wade, from Dallas Christian School, its
new President and CEO, effective August 1.?
"We
are delighted to partner with a person of Mr. Wade's integrity and commitment
to excellence in Christian education," said Bryan Shilcutt, chair of the ACS
Board of Trustees. "Kirk was well-loved by teachers and students at Dallas
Christian, and we look forward to his leadership at ACS and in the Abilene
community."
Wade
is a product of Christian education, graduating from Dallas Christian High
School in 1990 and Abilene Christian University with a bachelor's degree in
Education in 1994. He has a decade of experience as a teacher and coach at
Dallas Christian School and Forney Middle School.
In
2006, Wade earned a master's degree in Educational Administration from Texas
A&M-Commerce, and has since served in various administrative roles at
Dallas Christian over the last six years, including service as the Middle
School principal, Upper School principal and Interim President.?
Kirk
is married to Laura (Duff), from Abilene, and they have four children. Abilene Christian
Schools will host a reception to welcome the Wade family
on Thursday, August 8, from 3-5 p.m. in the ACS Board Room. The reception is
open to ACS families and the community.
City National Corp.'s second-quarter earnings rose 9%, making the L.A.-based private bank and business lender the latest California bank to exceed Wall Street's expectations.
The parent of City National Bank said Thursday that it posted a profit of $59.7 million, or $1.04 a share, compared with $54.8 million, or $1.01, in the same quarter last year. The average estimate of analysts as calculated by Thompson Financial Network was for earnings of just 96 cents a share.
It was the bank's 81st consecutive profitable quarter, said Chief Executive Russell Goldsmith, noting that assets, deposits and wealth-management fees all grew at a double-digit pace.?
Quiz: How much do you know about home loans?
Loans on the bank's books at the end of the quarter totaled $15.8 billion, excluding certain loans taken over from failed banks on which the Federal Deposit Insurance Corp. agreed to share losses.
That was up 17% year over year, making City National the latest California bank to surprise analysts with strong loan growth ? a development that bodes well for the economy as well as promising better earnings in quarters to come.
Aaron Deer, a San Francisco-based analyst at Sandler O?Neill, called the loan growth "great to see" because banks in hard-hit California??have been tripping over themselves over the past couple of years trying to find borrowers.?
?Any pickup in demand could signify that businesses are feeling better about the economic outlook and willing to invest in new opportunities,? Deer said.
City National announced the results after the close of trading. Its shares closed up $2.02, or 3.1%, at? $67.22.
The gain was a vote of confidence from investors who had seen other Southern California banks report favorable earnings after the markets closed Wednesday.
Among them were Citizens Business Bank parent CVB Financial Corp., whose shares jumped 5.6% on Thursday; Cathay General Bancorp, up 1.4%; and East West Bancorp, up 4.9%.?
ALSO:
Earnings, lending increase at Southland banks
City National: Bank to the stars -- and a lot more
Onward from Hollywood: City National tunes up in Music City
"The future is already here ? it's just not very evenly distributed," wrote William Gibson. He's right. Luckily, the future is mostly in my attic workshop. I've been lucky enough to have access to a Form 1 3D printer for the past week and have come away with a better sense of the platform, the way forward of 3D printing in general and Form 1 in particular. In short, the Form 1 is one of the simplest and most usable printers I've ever used and, barring a few minor peccadilloes, it is well worth the hype -- and price tag.
New compound excels at killing persistent and drug-resistant tuberculosisPublic release date: 17-Jun-2013 [ | E-mail | Share ]
Contact: Mika Ono mikaono@scripps.edu 858-784-2052 Scripps Research Institute
LA JOLLA, CA June 17, 2013 An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.
"These findings represent an effort to help solve one of the major global health crises of our timethe resurgence of TB and its dangerous drug-resistant strains," said Peter G. Schultz, the Scripps Family Chair Professor of Chemistry at TSRI, who was senior author of the study with William R. Jacobs, Jr., member of the Howard Hughes Medical Institute and professor of microbiology & immunology and of genetics at Albert Einstein College of Medicine.
"In cell cultures and in mice, this compound showed powerful activity against ordinary active TB bacteria, non-replicating TB bacteria and even extensively drug-resistant TB strains," said Feng Wang, a member of the Schultz lab at TSRI and first author of the study with Dhinakaran Sambandan of the Jacobs lab and Rajkumar Halder of the Schultz lab.
The paper appears in this week online ahead of print in an Early Edition of the Proceedings of the National Academy of Sciences.
Global Health Crisis
Although isoniazid and rifampin, the two front-line TB drugs, came into use in 1952 and 1967 respectively, new TB infections still occur at the rate of roughly one per second. At any moment about a third of the existing human population is infectedmostly with inactive, latent TB, although active TB still kills over one million people each year. Russia, Africa, China and Southeast Asia have been especially hard hit by the epidemic.
Increased urbanization, public health complacency and immunity-weakening HIV have been major enablers of TB's spread in recent decades. But the bacterium that causes TBMycobacterium tuberculosis (Mtb)also happens to be unusually well adapted for persisting in humans. Among other strategies, it frequently reverts to a dormant, non-replicating state and also creates attack-resistant cell colonies called biofilms, which contain a high proportion of non-replicating TB.
Compared to ordinary, fast-replicating TB, these other forms of TB are much less susceptible to existing drugs. Effective TB therapy thus requires months to years of regular dosing. But many patients quit before completing such long courses of treatment and end up incubating drug-resistant TB strains. Some strains are now "extensively drug-resistant" (XDR) and virtually untreatableand usually fatal.
Killing the Persisters
"The big challenge here has been to find a drug that clears TB infection more quickly, which means it has to be effective against both replicating and non-replicating TB," said Wang, now also a scientist at the California Institute for Biomedical Research (CALIBR), a non-profit organization founded by Schultz for the early-stage development of new medicines.
Most existing TB drugs work poorly against non-replicating TB, having been developed principally for their ability to kill actively replicating TB. Wang therefore set up a different kind of screening testone to detect compounds that block TB's persistence-related ability to form biofilms.
Because experiments with live TB require a special (level 3) biosafety facility, Wang used a related but non-disease-causing mycobacterium for his initial, high-throughput test. Screening a diverse library of 70,000 compounds, he quickly found one, dubbed TCA1, that stood out for its ability to inhibit mycobacterial biofilms.
Tests in Jacobs's biosafety level 3-certified laboratory confirmed that TCA1 also has powerful activity against TB. "Surprisingly, it turned out to kill both non-replicating and replicating TB," Wang said.
In cell culture tests, TCA1 on its own killed more than 99.9% of ordinary, actively replicating TB bacteria within three weeks, and in combination with isoniazid or rifampin, could kill 100% within that period. TCA1 also showed strong effectiveness against drug-resistant TB strains, removing all signs of one common strain within a week when combined with isoniazid. Against a highly fatal "super-bug" strain from South Africa, which resists all conventional TB drugs, the new compound on its own had a kill rate of more than 99.999% within three weeks.
As expected, TCA1 also showed potent effects against non-replicating TB. Tests in mice confirmed TCA1's effectiveness and suggested that the combination of TCA1 and isoniazid could be more powerful than existing drug regimens. TCA1 showed no sign of toxicity or adverse side effects in cell culture and mouse experiments, and also showed almost no tendency to induce drug resistance in TB.
A Complex Mechanism
Working with the laboratories of Gurdyal S. Besra and Klaus Ftterer at the University of Birmingham, UK, Katarina Mikusova at Comenius University in Slovakia, and Kai Johnson at Ecole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland, the team next did structural and biochemical analyses to determine how the new compound kills Mtb so efficiently.
The researchers found it works in an apparently unique way, largely by targeting two Mtb enzymes, one supporting TB replication and the other TB dormancy and persistence. "I don't know of any other antibiotic that kills replicating bacteria through one pathway and non replicating bacteria through another, as this one does," Wang said.
Now funded by the Global Alliance for TB Drug Development, Wang and his colleagues are working to devise improved variants of TCA1. "We already have analogs of TCA1 that are more potent and look very promising as TB drug candidates," said Wang.
Assuming that preclinical tests are completed successfully, he added, the group hopes to find a pharmaceutical company partner to sponsor clinical trials in TB patients.
###
Contributors to the study, "Identification of a small molecule with activity against drug-resistant and persistent tuberculosis," also included Jianing Wang, Insha Ahmad, Pengyu Yang and Yong Zhang of TSRI; Sarah M. Batt of University of Birmingham; Brian Weinrick, John Kim and Morad Hassani of Howard Hughes Medical Institute and Albert Einstein College of Medicine; Stanislav Huszar of Comenius University (Slovakia); Claudia Trefzer of EPFL; Zhenkun Ma, Takushi Kaneko and Khisi E. Mdluli of the Global Alliance for Tuberculosis Drug Development; Scott Franzblau of the University of Illinois; and Arnab K. Chatterjee of CALIBR.
The study was funded in part by the National Institutes of Health (grants AI26170 and A10-97548), the European Community's Seventh Framework Programme (260872), the Global Alliance for TB Drug Development and the Albert Einstein College of Medicine Center for AIDS Research (AI051519).
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
New compound excels at killing persistent and drug-resistant tuberculosisPublic release date: 17-Jun-2013 [ | E-mail | Share ]
Contact: Mika Ono mikaono@scripps.edu 858-784-2052 Scripps Research Institute
LA JOLLA, CA June 17, 2013 An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.
"These findings represent an effort to help solve one of the major global health crises of our timethe resurgence of TB and its dangerous drug-resistant strains," said Peter G. Schultz, the Scripps Family Chair Professor of Chemistry at TSRI, who was senior author of the study with William R. Jacobs, Jr., member of the Howard Hughes Medical Institute and professor of microbiology & immunology and of genetics at Albert Einstein College of Medicine.
"In cell cultures and in mice, this compound showed powerful activity against ordinary active TB bacteria, non-replicating TB bacteria and even extensively drug-resistant TB strains," said Feng Wang, a member of the Schultz lab at TSRI and first author of the study with Dhinakaran Sambandan of the Jacobs lab and Rajkumar Halder of the Schultz lab.
The paper appears in this week online ahead of print in an Early Edition of the Proceedings of the National Academy of Sciences.
Global Health Crisis
Although isoniazid and rifampin, the two front-line TB drugs, came into use in 1952 and 1967 respectively, new TB infections still occur at the rate of roughly one per second. At any moment about a third of the existing human population is infectedmostly with inactive, latent TB, although active TB still kills over one million people each year. Russia, Africa, China and Southeast Asia have been especially hard hit by the epidemic.
Increased urbanization, public health complacency and immunity-weakening HIV have been major enablers of TB's spread in recent decades. But the bacterium that causes TBMycobacterium tuberculosis (Mtb)also happens to be unusually well adapted for persisting in humans. Among other strategies, it frequently reverts to a dormant, non-replicating state and also creates attack-resistant cell colonies called biofilms, which contain a high proportion of non-replicating TB.
Compared to ordinary, fast-replicating TB, these other forms of TB are much less susceptible to existing drugs. Effective TB therapy thus requires months to years of regular dosing. But many patients quit before completing such long courses of treatment and end up incubating drug-resistant TB strains. Some strains are now "extensively drug-resistant" (XDR) and virtually untreatableand usually fatal.
Killing the Persisters
"The big challenge here has been to find a drug that clears TB infection more quickly, which means it has to be effective against both replicating and non-replicating TB," said Wang, now also a scientist at the California Institute for Biomedical Research (CALIBR), a non-profit organization founded by Schultz for the early-stage development of new medicines.
Most existing TB drugs work poorly against non-replicating TB, having been developed principally for their ability to kill actively replicating TB. Wang therefore set up a different kind of screening testone to detect compounds that block TB's persistence-related ability to form biofilms.
Because experiments with live TB require a special (level 3) biosafety facility, Wang used a related but non-disease-causing mycobacterium for his initial, high-throughput test. Screening a diverse library of 70,000 compounds, he quickly found one, dubbed TCA1, that stood out for its ability to inhibit mycobacterial biofilms.
Tests in Jacobs's biosafety level 3-certified laboratory confirmed that TCA1 also has powerful activity against TB. "Surprisingly, it turned out to kill both non-replicating and replicating TB," Wang said.
In cell culture tests, TCA1 on its own killed more than 99.9% of ordinary, actively replicating TB bacteria within three weeks, and in combination with isoniazid or rifampin, could kill 100% within that period. TCA1 also showed strong effectiveness against drug-resistant TB strains, removing all signs of one common strain within a week when combined with isoniazid. Against a highly fatal "super-bug" strain from South Africa, which resists all conventional TB drugs, the new compound on its own had a kill rate of more than 99.999% within three weeks.
As expected, TCA1 also showed potent effects against non-replicating TB. Tests in mice confirmed TCA1's effectiveness and suggested that the combination of TCA1 and isoniazid could be more powerful than existing drug regimens. TCA1 showed no sign of toxicity or adverse side effects in cell culture and mouse experiments, and also showed almost no tendency to induce drug resistance in TB.
A Complex Mechanism
Working with the laboratories of Gurdyal S. Besra and Klaus Ftterer at the University of Birmingham, UK, Katarina Mikusova at Comenius University in Slovakia, and Kai Johnson at Ecole Polytechnique Fdrale de Lausanne (EPFL) in Switzerland, the team next did structural and biochemical analyses to determine how the new compound kills Mtb so efficiently.
The researchers found it works in an apparently unique way, largely by targeting two Mtb enzymes, one supporting TB replication and the other TB dormancy and persistence. "I don't know of any other antibiotic that kills replicating bacteria through one pathway and non replicating bacteria through another, as this one does," Wang said.
Now funded by the Global Alliance for TB Drug Development, Wang and his colleagues are working to devise improved variants of TCA1. "We already have analogs of TCA1 that are more potent and look very promising as TB drug candidates," said Wang.
Assuming that preclinical tests are completed successfully, he added, the group hopes to find a pharmaceutical company partner to sponsor clinical trials in TB patients.
###
Contributors to the study, "Identification of a small molecule with activity against drug-resistant and persistent tuberculosis," also included Jianing Wang, Insha Ahmad, Pengyu Yang and Yong Zhang of TSRI; Sarah M. Batt of University of Birmingham; Brian Weinrick, John Kim and Morad Hassani of Howard Hughes Medical Institute and Albert Einstein College of Medicine; Stanislav Huszar of Comenius University (Slovakia); Claudia Trefzer of EPFL; Zhenkun Ma, Takushi Kaneko and Khisi E. Mdluli of the Global Alliance for Tuberculosis Drug Development; Scott Franzblau of the University of Illinois; and Arnab K. Chatterjee of CALIBR.
The study was funded in part by the National Institutes of Health (grants AI26170 and A10-97548), the European Community's Seventh Framework Programme (260872), the Global Alliance for TB Drug Development and the Albert Einstein College of Medicine Center for AIDS Research (AI051519).
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
The park that was the center of defiance against the rule of Turkish Prime Minister Recep Tayyip Erdogan has been cleared by riot police after more than two weeks of protests. As thousands of demonstrators try to regroup in Taksim Square, smaller skirmishes between police and protesters have broken out in other parts of Istanbul.
Here's a gallery of images from the past two weeks of protests and pushback in Turkey.
Follow AP photographers and photo editors on Twitter: http://apne.ws/15Oo6jo
23 July 2013, Lagos ? As part of measures put in place to boost electricity supply in the country, Nigeria and India have concluded plans to set up an off-grid solar powered system across selected locations in Nigeria.
"The future is already here ? it's just not very evenly distributed," wrote William Gibson. He's right. Luckily, the future is mostly in my attic workshop. I've been lucky enough to have access to a ![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vy9XsJwJCIiPJ_btx5ioG8cw2dOHkL1dOKSQOPmWrmxKXcwF6VpykFtVkrZ0MPbCBkOIp5OT2zGGwFCGmnCMEQ3Z3P5LcjGBqgmSPLoX4=s0-d){kind=small}
Public release date: 17-Jun-2013
Share ]